Literature DB >> 16920487

Mphi1 and Mphi2 can be re-polarized by Th2 or Th1 cytokines, respectively, and respond to exogenous danger signals.

Alexei Gratchev1, Julia Kzhyshkowska, Kirsten Köthe, Isabelle Muller-Molinet, Sheila Kannookadan, Jochen Utikal, Sergij Goerdt.   

Abstract

Macrophages (Mphi) represent a dynamic cell population that develops and operates within a changing microenvironment. In parallel to Th1/Th2 cells, primary Mphi may undergo classical (Mphi1) or alternative (Mphi2) activation. Here, we investigated whether Mphi1/Mphi2 may be re-polarized by a secondary stimulation by Th1 or Th2 cytokines or by exogenous danger signals. We established that Mphi1IFNgamma respond to alternative activation by IL-4 and IL-10 by de novo secretion of Th2 cytokines AMAC-1 and IL-1ra, and by an increase in phagocytic capacity and a decrease in bactericidal activity. Vice versa, Mphi2 responded to classical activation by IFNgamma exhibiting reduced phagocytosis and significantly increased bacterial killing while being refractory regarding secretion of TNFalpha, IL-1beta and IL-12. In response to the bacterial danger signals LPS and MDP, both Mphi1 and Mphi2 produced IL-1beta and TNFalpha; in addition Mphi2 expressed the Th1-inducing cytokine IL-12. The ability of Mphi to be re-polarized and to react to exogenous danger signals is a precondition to down-regulate an outdated immune reaction and to retain the capacity to mount an adequate anti-bacterial response. Selective refractoriness of Mphi1 and Mphi2 to IFNgamma- and LPS-induced cytokine secretion may contribute to prevent autoimmunity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16920487     DOI: 10.1016/j.imbio.2006.05.017

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  66 in total

1.  Overcoming endogenous constraints on neuronal regeneration.

Authors:  Nassir Mokarram; Ravi V Bellamkonda
Journal:  IEEE Trans Biomed Eng       Date:  2010-12-30       Impact factor: 4.538

2.  Novel macrophage polarization model: from gene expression to identification of new anti-inflammatory molecules.

Authors:  Gloria Lopez-Castejón; Alberto Baroja-Mazo; Pablo Pelegrín
Journal:  Cell Mol Life Sci       Date:  2010-12-28       Impact factor: 9.261

Review 3.  Engineering biomaterials to integrate and heal: the biocompatibility paradigm shifts.

Authors:  James D Bryers; Cecilia M Giachelli; Buddy D Ratner
Journal:  Biotechnol Bioeng       Date:  2012-05-24       Impact factor: 4.530

Review 4.  Obstacles and opportunities for understanding macrophage polarization.

Authors:  Peter J Murray; Thomas A Wynn
Journal:  J Leukoc Biol       Date:  2011-01-19       Impact factor: 4.962

Review 5.  Microglia and inflammation in Alzheimer's disease.

Authors:  Shweta Mandrekar-Colucci; Gary E Landreth
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-04       Impact factor: 4.388

Review 6.  Macrophage diversity in cardiac inflammation: a review.

Authors:  Jobert G Barin; Noel R Rose; Daniela Ciháková
Journal:  Immunobiology       Date:  2011-06-30       Impact factor: 3.144

7.  Intravenous immunoglobulin suppresses the polarization of both classically and alternatively activated macrophages.

Authors:  Chaitrali Saha; Prathap Kothapalli; Veerupaxagouda Patil; Gundallahalli Bayyappa ManjunathaReddy; Srini V Kaveri; Jagadeesh Bayry
Journal:  Hum Vaccin Immunother       Date:  2019-05-07       Impact factor: 3.452

Review 8.  Advances in peripheral nerve regeneration.

Authors:  Jami Scheib; Ahmet Höke
Journal:  Nat Rev Neurol       Date:  2013-11-12       Impact factor: 42.937

9.  Adenosine 5'-monophosphate-activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype.

Authors:  Duygu Sag; David Carling; Robert D Stout; Jill Suttles
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

Review 10.  Heterogeneity of microglial activation in the innate immune response in the brain.

Authors:  Carol A Colton
Journal:  J Neuroimmune Pharmacol       Date:  2009-08-05       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.